Professor Johann de Bono’s group investigates new molecular targeted therapies to improve the treatment of patients with advanced prostate cancer.
Professor Johann de Bono is the Head of the Division of Clinical Studies and an international expert in the development of novel anticancer therapies against adult cancers. His group of runs one of the world’s largest phase I clinical trials units for cancer, with >100 staff including dedicated radiology and pathology staff; he also runs a separate group focused on improving prostate cancer care that have led pivotal phase III trials of several prostate cancer drugs including abiraterone, cabazitaxel, enzalutamide and olaparib as well more recently ipatasertib and lutetium-PSMA.